QLS2309

· Qilu Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for QLS2309, covering 2026-01-02 to 2026-01-02. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies [Phase 1]

See pricing